Industry
Dechra completes purchase of cell therapy company Gallant Pet
The deal gives Dechra a pipeline of ready-to-use mesenchymal stromal cell therapies. The company says the first product could reach market as early as 2027.
VetStack NewsSource: Today's Veterinary Business
The deal
Dechra has finished acquiring Gallant Pet, Today's Veterinary Business reported. Gallant is a US animal health biotechnology company that develops off-the-shelf mesenchymal stromal cell (MSC) therapies.
The companies did not disclose financial terms.
What Dechra is getting
Dechra said the purchase gives it a new therapeutic platform aimed at chronic and complex conditions. According to the company, the therapies are meant to work with a patient's own biological processes.
Gallant's regenerative medicine pipeline includes therapies meant for several conditions in more than one animal species. Dechra describes them as targeting the underlying causes of disease.